William Blair keeps an Outperform rating on Denali Therapeutics (DNLI) after the company announced that a biologics license application for tividenofusp alfa was accepted by the FDA for the treatment of Hunter syndrome under the accelerated approval pathway. Management in a follow-up call noted no mention of an FDA advisory committee meeting as part of the review process at this time, which is a positive, the analyst tells investors in a research note. Blair believes the data support a “potential best-in-class treatment option.” It expects global peak sales of tividenofusp of $784M and views Denali as an “undervalued late-stage biotech name.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics’ FDA Priority Review for New Therapy
- Denali announces FDA acceptance, priority review for tividenofusp alfa BLA
- Denali Therapeutics Enters Registration Rights Agreement
- Denali Therapeutics price target lowered to $27 from $28 at BofA
- Denali Therapeutics price target lowered to $30 from $35 at B. Riley